Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

Stopped early · Phase 2

Conditions studied: Acute Heart Failure

In brief

The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of an intravenous infusion of serelaxin on top of standard of care therapy, in pediatric patients with acute heart failure (AHF)

Key facts

Study ID

NCT02151383

Run by

Novartis Pharmaceuticals

People needed

12

Starts

2014-09-05

Expected to finish

2017-04-03

Last updated by the study team

2019-06-25

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Denver, Colorado, United States
• Novartis Investigative Site — St Louis, Missouri, United States
• Novartis Investigative Site — The Bronx, New York, United States
• Novartis Investigative Site — Philadelphia, Pennsylvania, United States
• Novartis Investigative Site — Charleston, South Carolina, United States
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Freiburg im Breisgau, Germany
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — Geneva, Switzerland
• Novartis Investigative Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.